Risk factor modification in intermittent claudication: Effect on life expectancy and walking capacity

European Heart Journal, Supplement

Volumn 4, Issue B, 2002, Pages

  Hiatt, William R ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Intermittent claudication; Peripheral arterial disease

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PROPIONYLCARNITINE; TICLOPIDINE; TRIACYLGLYCEROL;

AGE; ARTERIAL CIRCULATION; ARTERY DISEASE; ATHEROSCLEROSIS; BYPASS SURGERY; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CLINICAL FEATURE; CLINICAL TRIAL; DIABETES CONTROL; DIABETES MELLITUS; DRUG EFFICACY; ECHOGRAPHY; EUROPE; EXERCISE; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTERMITTENT CLAUDICATION; LEG ISCHEMIA; LIFE EXPECTANCY; MAGNETIC RESONANCE ANGIOGRAPHY; META ANALYSIS; MORBIDITY; MORTALITY; PHYSICAL CAPACITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR MODIFICATION; RISK MANAGEMENT; SECONDARY PREVENTION; SIDE EFFECT; STROKE; TREADMILL EXERCISE; TREATMENT INDICATION; UNITED STATES; WALKING;

EID: 0041783636     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1520-765X(02)90018-0     Document Type: Review

References (31)

1. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001; 344: 1608-21.
2. Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley diabetes study. Circulation 1995; 91: 1472-9.
3. Beach KW, Strandness DE. Arteriosclerosis obliterans and associated risk factors in insulin-dependent and non-insulin-dependent diabetes. Diabetes 1980; 29: 882-8.
4. Anonymous. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995; 75: 894-903.
5. Anonymous. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-53.
6. Estacio RO, Jeffers BW, Hiatt WR et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645-52.
7. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intem Med 1999; 131: 281-303.
8. Murabito JM, D'Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation 1997; 96: 44-9.
9. Quick CRG, Cotton LT. The measured effect of stopping smoking on intermittent claudication. Br J Surg 1982; 69(suppl): S24-6.
10. Stewart CP. The influence of smoking on the level of lower limb amputation. Prosthet Orthot Int 1987; 11: 113-6.
11. Jonason T, Bergstrom R. Cessation of smoking in patients with intermittent claudication. Acta Med Scand 1987; 221: 253-60.
12. Girolami B, Bemardi F, Prins MH et al. Treatment of intermittent claudication with physical training smoking cassation, pentoxfylline, or nafronyl: a meta-analysis. Arch Intem Med 1999; 159: 337-45.
13. Elam MB, Hunninghake DB, Davis KB et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 2000; 284: 1263-70.
14. Leng GC, Price JF, Jepson RG. Lipid-lowering for lower limb atherosclerosis (Cochrane Review). In: The Cochrane Library. Oxford, Update Software, 1999.
15. Pedersen TR, Kjekshus J, Pyorala K et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol 1998; 81: 333-5.
16. Kahn F, Litchfield SJ, Belch JJ. Cutaneous microvascular responses are improved after cholesterol-lowering in patients with peripheral arterial disease. Adv Exp Med Biol 1997; 428: 49-54.
17. Anonymous. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
18. Ansell BJ, Watson KE, Fogelman AM. An evidence-based assessment of NCEP Adult Treatment Panel II guidelines. National Cholesterol Education Program. JAMA 1999; 282: 2051-7.
19. Anonymous. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413-46.
20. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 1991; 151: 1769-76.
21. Poldermans D, Boersma E, Bax JJ et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. N Engl J Med 1999; 341: 1789-94.
22. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.
23. Anonymous. Collaborative overview of randomised trials of antiplatelet therapy. I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994; 308: 81-106.
24. Anonymous. Collaborative overview of randomised trials of antiplatelet therapy. II: maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists' Collaboration. BMJ 1994; 308: 159-68.
25. Goldhabez SZ, Manson JE, Stampfer MJ et al. Low-dose aspirin and subsequent arterial surgery in the Physician Health Study. Lancet 1992; 340: 143-5.
26. Berqvist D, Almgren B, Dickinson JP. Reduction of requirement for leg vascular surgery during long-term treatment of claudicant patients with ticlopidine: results from the Swedish Ticlopidine Multicentre Study (STIMS). Eur J Vasc Endovasc Surg 1995; 10: 69-76.
27. Bokissel JP, Peyrieux JC, Destors JM. Is it possible to reduce the risk of cardiovascular events in subjects suffering from intermittent claudication of the lower limbs? Thromb Haemost 1996; 62: 681-5.
28. Arcan JC, Blanchard J, Boissel JP, Destors JM, Panak E. Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications. Angiology 1988; 39: 802-11.
29. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
30. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA 1995; 274: 975-80.
31. Regensteiner JG, Steiner JF, Hiatt WR. Exercise training improves functional status in patients with peripheral arterial disease. J Vasc Surg 1996; 23: 104-15.